What is the current Price Target for the Virios Therapeutics Inc stock?

The average Virios Therapeutics Inc target price is $25.00. This is 430.79% higher than the current stock price. 1 Analyst has issued a Virios Therapeutics Inc price target 2026.

How high will the Virios Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Virios Therapeutics Inc stock will rise. The performance of stocks, including the Virios Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Virios Therapeutics Inc stock today?

The performance of Virios Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Virios Therapeutics Inc stock fall?

The decline in Virios Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Virios Therapeutics Inc Forecast, price target & analysts

$4.78

1.49% today

Nasdaq, Feb 28, 09:32 pm CET

ISIN

US92829J1043

Symbol

DWTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Virios Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Virios Therapeutics Inc Classifications & Recommendation:

Buy

100%

Virios Therapeutics Inc Price Target

Target Price	$25.00
Price	$4.71
Potential	430.79% register free of charge
Number of Estimates	1

	1 Analyst has issued a Virios Therapeutics Inc price target 2026. The average Virios Therapeutics Inc target price is $25.00. This is 430.79% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 1 Analysts recommend Virios Therapeutics Inc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Virios Therapeutics Inc stock has an average upside potential 2026 of 430.79% register free of charge . Most analysts recommend the Virios Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-7.05	-6.03
	74.51%	14.47%
P/E		negative

1 Analysts have issued a Virios Therapeutics Inc forecast for earnings per share. The average Virios Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$-7.05	74.51%
2024	$-6.03 14.47% Unlock
2025	$-10.30 70.81% Unlock
2026	$-3.94 61.75% Unlock
2027	$-5.03 27.66% Unlock
2028	$-5.81 15.51% Unlock

Current	-0.75	23.47%
2024	-0.78 4.00% Unlock
2025	-0.46 41.03% Unlock
2026	-1.20 160.87% Unlock
2027	-0.94 21.67% Unlock
2028	-0.81 13.83% Unlock

Virios Therapeutics Inc...

Current Virios Therapeutics Inc Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 09 2024

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 09 2024

Discover more stocks with a high price target

Coinbase Global, Inc. 60.51%

BioNTech SE - ADR 30.07%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now